Lv4
460 积分 2023-02-05 加入
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
14小时前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
12天前
已完结
Comprehensive characterization of early-onset lung cancer, in Chinese young adults
1个月前
已完结
Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials
2个月前
已完结
Radiotheranostic landscape: A review of clinical and preclinical development
2个月前
已完结
The present and future of bispecific antibodies for cancer therapy
2个月前
已完结
Cancer therapy with antibodies
2个月前
已完结
Chinese innovative drug R&D trends in 2024
2个月前
已完结
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
2个月前
已完结
A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor
2个月前
已完结
皖公网安备34019202002308
